ADXS News 2.71 04/24/2014 04:49:42 Advaxis Inc (ADXS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Advaxis Inc (ADXS) 2.71 $ADXS

Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030.

Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Tue Apr 01, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for three U.S. patent applications (12/213,696, 13/254,607, and 11/415,271) with claims of each application related to the Company's proprietary cancer immunotherapy platform technology. The patent with the latest date of expiry is 2030, without taking into account patent term extension.

Advaxis Announces Closing of Public Offering of Common Stock
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the closing of a previously announced underwritten public offering of 4,692,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 612,000 shares, offered at a price to the public of $3.00 per share. The gross proceeds to the Company were $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Moskowitz: Advaxis Balance Sheet Shored Up
ACCESSWIRE - Mon Mar 31, 8:40AM CDT
Read the Advaxis Report Update: http://equitiesiq.com/reports/advaxis-update/

Advaxis Announces Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Fri Mar 28, 2:00PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 612,000 shares of its common stock at a public offering price of $3.00 per share in connection with its previously announced underwritten public offering of 4,080,000 shares of common stock, bring the total gross proceeds from the offering to approximately $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Team Nation Holdings Corp Officially Changes its Name; Petr Shares Rise on Brazil Outlook Upgrade
ACCESSWIRE - Thu Mar 27, 11:37PM CDT
Petr (NYSE: PBR) - For an in-depth report on Petr follow: www.BullTrends.com/stockquote/PBR

Nasdaq stocks posting largest volume increases
AP - Thu Mar 27, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Advaxis Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Mar 26, 7:40PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the pricing of an underwritten public offering of 4,080,000 shares of common stock at a public offering price of $3.00 per share. The Company expects to receive $12,240,000 in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters a 45-day option to purchase up to 612,000 additional shares of common stock. The Company intends to use the net proceeds from this offering to fund the Company's continued research and development initiatives in connection with expanding its product line and for other general corporate purposes.

Advaxis Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Mar 26, 3:08PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced that it intends to offer for sale shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering to fund the Company's continued research and development initiatives in connection with expanding its product line and for other general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Advaxis, Inc. [ADXS] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Mar 26, 11:10AM CDT
What:

Advaxis to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Mar 26, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that its management team will ring The NASDAQ Stock Market Closing Bell on Thursday, March 27, 2014.

Advaxis Appoints Sara Bonstein as Chief Financial Officer, Senior Vice President
GlobeNewswire - Mon Mar 24, 4:16PM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has appointed Sara Bonstein to the position of Chief Financial Officer, Senior Vice President. Ms. Bonstein has a decade of financial leadership experience in the life sciences industry with Eli Lilly & Company, ImClone Systems, and Johnson & Johnson.

Advaxis, Inc. "A Win-Win in Pet Therapeutics"
ACCESSWIRE - Fri Mar 21, 8:21AM CDT
Philadelphia, PA / ACCESSWIRE / March 21, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's EVP and COO, Mr. Gregory T. Mayes. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Advaxis Discusses Global Licensing Agreement for Pet Therapeutics on Conference Call
GlobeNewswire - Thu Mar 20, 11:45AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, hosted a joint conference call with Aratana Therapeutics (Nasdaq ETX) today at 8:00 am ET to discuss the recently announced global licensing agreement for Advaxis's ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer.

Aratana and Advaxis Enter Exclusive Global Licensing Agreement
PR Newswire - Wed Mar 19, 7:01PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer. Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing for the treatment of human cancers on a global basis. Under the agreement, Aratana will have exclusive rights to develop and commercialize the licensed immunotherapies for pet health applications, and will focus initially on developing ADXS-cHER2 for osteosarcoma.

Advaxis Receives Patent in Japan for ADXS-HPV for the Treatment of Cervical Cancer
GlobeNewswire - Tue Mar 18, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that it has been issued a significant patent from the Japan Patent Office, entitled, "Compositions and Methods for Enhancing Immunogenicity of Antigens". The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028.

Advaxis and UC San Francisco to Evaluate Cancer Immunotherapy Constructs in Prostate Cancer
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has signed an agreement with the University of California, San Francisco (UCSF), under which Lawrence Fong, M.D., Professor in the Department of Medicine and principal investigator of the studies at UCSF, will evaluate several new immunotherapy constructs, in addition to ADXS-PSA, each built on the Advaxis proprietary technology. Data generated from this agreement will demonstrate the combination of the unique Advaxis immunotherapy platform, which generates both tumor fighting T cells and reduces tumor protection inside the tumor microenvironment, with targets that have already been shown to be important in effective immunotherapies for prostate cancer.

Advaxis to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
GlobeNewswire - Thu Mar 13, 8:01AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that the company will present at the 2 Annual Sachs Cancer Bio Partnering & Investment Forum on Wednesday, March 19 at the New York Academy of Sciences. Robert G. Petit, Ph.D., Chief Scientific Officer of Advaxis, will serve on an expert panel titled "Immunotherapies and Cancer Vaccines" at 11:45am and Daniel J. O'Connor, Chief Executive Officer of Advaxis, will present an update on the Company at 1:30pm.

Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 183

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 6

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading
Limina’s Amberflo Deal Makes AI Usage Visible at Scale

Updated Category News Views 32

Enterprise AI has created a billing fog, and Limina just bought itself a flashlight. Its merger with Amberflo, completed on October 30 and announced November 19, brings metering, cost attribution, and billing technology fully inside Limina’s data-governance platform. No price was disclosed, which is irritating but ordinary for a transaction involving companies that do...

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 96

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 51

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
PTC Pushes Deeper Into Federal Product Development

Updated Category News Views 14

Federal engineering software is a miserable place to show up late, and PTC is plainly trying not to. Its November 19, 2026 expansion brings Windchill+ onto Microsoft Azure Government through PTC Cloud Services and introduces Onshape Government Federal for teams handling Controlled Unclassified Information. This is not a glamorous product refresh. It is a bid to remove the...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 60

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Mindgruve's Tech Hire Puts Sightline Growth in Focus

Updated Category News Views 67

Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...

Continue Reading
CMA Wins Spotlight Greenberg Traurig’s Music Bench

Updated Category News Views 34

Four trophies on one awards night can say plenty about the machinery behind a music career, even if nobody should confuse a CMA acceptance speech with a balance-sheet event. Greenberg Traurig’s entertainment practice is celebrating client wins at the 60th annual CMA Awards, held Nov. 18, 2026: three honors tied to Miranda Lambert and one for Brooks & Dunn. For investors...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 54

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading

Top 5 Most Recently Viewed Articles

Home Depot Shines While the Market Treads Water—Notable Trends

Updated Category News Views 192

Market Overview There’s a certain chaos in the markets, right? U.S. stocks kicked off the week with a little bit of everything, a wild cocktail of ups and downs. The Dow, surprisingly, snagged a gain of over 100 points, closing up 0.27% at 48,935.82. But don’t get too comfy—NASDAQ took a hit, dropping about 0.39% to 22,538.28 while the S&P 500 stumbled down by 0.30%...

Continue Reading
Piston-Single Aircraft Inventory Shows Positive Trends Ahead

Updated Category News Views 106

Piston-Single Aircraft Inventory Shows Positive Trends Ahead In recent months, the aviation market has demonstrated notable resilience, particularly in the segment of used piston-single aircraft. Inventory data indicates a gradual recovery, showcasing a shift from the lows witnessed earlier this year. Despite a decline in overall inventory levels compared to last year,...

Continue Reading
K92 Mining Reports Significant Q2 Results and Expansion Plans

Updated Category News Views 215

K92 Mining Reports Strong Q2 Production Results K92 Mining Inc. (“K92”) (TSX: KNT; Other OTC: KNTNF) has recently shared its robust production performance for the second quarter. This impressive quarterly production total from the Kainantu Gold Mine showcases the upward trajectory of the company within the mining sector. Highlights of Q2 2025 Production The production...

Continue Reading
Explore Top Dividend Stocks to Consider Investing In

Updated Category News Views 105

Dividend Opportunities in Today's Market As the year unfolds, many investors are exploring alternatives to traditional fixed-income investments due to changing interest rates. Shifting focus to dividend-paying stocks can offer both steady income and the potential for capital appreciation. Realty Income (NYSE: O), Costco Wholesale (NASDAQ: COST), and Royal Caribbean...

Continue Reading
Braemar Hotels & Resorts Secures $115 Million Sale of The Clancy

Updated Category News Views 176

Braemar Hotels & Resorts Announces Sale Agreement for The Clancy DALLAS – Braemar Hotels & Resorts Inc. (NYSE: BHR) has officially entered into a significant agreement to sell its San Francisco property, The Clancy. This strategic move reflects the company's ongoing commitment to enhance its investment portfolio and maximize value for shareholders by divesting...

Continue Reading